JP2021503455A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021503455A5 JP2021503455A5 JP2020526566A JP2020526566A JP2021503455A5 JP 2021503455 A5 JP2021503455 A5 JP 2021503455A5 JP 2020526566 A JP2020526566 A JP 2020526566A JP 2020526566 A JP2020526566 A JP 2020526566A JP 2021503455 A5 JP2021503455 A5 JP 2021503455A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- seq
- acid sequence
- cdr2
- cdr3
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2017111712 | 2017-11-17 | ||
| CNPCT/CN2017/111712 | 2017-11-17 | ||
| PCT/CN2018/115213 WO2019096121A1 (en) | 2017-11-17 | 2018-11-13 | Single-domain antibodies and variants thereof against pd-l1 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021503455A JP2021503455A (ja) | 2021-02-12 |
| JP2021503455A5 true JP2021503455A5 (enExample) | 2021-12-09 |
| JP7410024B2 JP7410024B2 (ja) | 2024-01-09 |
Family
ID=66538525
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020526566A Active JP7410024B2 (ja) | 2017-11-17 | 2018-11-13 | Ｐｄ－ｌ１に対する単一ドメイン抗体とその多様体 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US11673954B2 (enExample) |
| EP (1) | EP3710480A4 (enExample) |
| JP (1) | JP7410024B2 (enExample) |
| KR (1) | KR102810657B1 (enExample) |
| CN (1) | CN111433224B (enExample) |
| AU (1) | AU2018366650B2 (enExample) |
| CA (1) | CA3081375A1 (enExample) |
| IL (1) | IL274438A (enExample) |
| SG (1) | SG11202004144VA (enExample) |
| TW (1) | TW201923083A (enExample) |
| WO (1) | WO2019096121A1 (enExample) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3802613A4 (en) * | 2018-06-05 | 2022-03-09 | Jiangsu Alphamab Biopharmaceuticals Co., Ltd. | DIMER AND ITS USE |
| CN112409483B (zh) * | 2019-08-22 | 2024-08-27 | 浙江道尔生物科技有限公司 | 抗pd-l1纳米抗体 |
| CN112480253B (zh) * | 2019-09-12 | 2022-09-20 | 普米斯生物技术(珠海)有限公司 | 一种抗pd-l1纳米抗体及其衍生物和用途 |
| WO2021057836A1 (en) | 2019-09-25 | 2021-04-01 | Wuxi Biologics (Shanghai) Co. Ltd. | Novel anti-pd-l1 antibodies |
| KR20220087488A (ko) * | 2019-10-30 | 2022-06-24 | 산유 바이오파마슈티컬스 씨오., 엘티디. | Pd-l1 결합 분자 |
| AU2021205565A1 (en) | 2020-01-10 | 2022-07-28 | Shanghai Henlius Biotech, Inc. | Anti-TIGIT antibodies, multispecific antibodies comprising the same and methods of using the same |
| JP7512413B2 (ja) * | 2020-03-31 | 2024-07-08 | ビオテウス・インコーポレイテッド | 抗ｐｄ－ｌ１およびｐｄ－ｌ２抗体ならびにその誘導体および用途 |
| WO2021213435A1 (zh) * | 2020-04-22 | 2021-10-28 | 迈威(上海)生物科技股份有限公司 | 一种靶向人程序性死亡配体1(pd-l1)的单可变域抗体及其衍生物 |
| CN114106190B (zh) | 2020-08-31 | 2025-04-08 | 普米斯生物技术(珠海)有限公司 | 一种抗vegf/pd-l1双特异性抗体及其用途 |
| EP3992208A1 (en) * | 2020-11-03 | 2022-05-04 | Randox Laboratories Ltd | Anti-pd-l1 vhh antibodies |
| CA3201560A1 (en) * | 2020-12-08 | 2022-06-16 | David Campbell | Half-life extending compositions and methods |
| US11555078B2 (en) | 2020-12-09 | 2023-01-17 | Janux Therapeutics, Inc. | Compositions and methods related to tumor activated antibodies targeting PSMA and effector cell antigens |
| US11685784B2 (en) * | 2021-03-24 | 2023-06-27 | China Medical University Hospital | Anti-immune-checkpoint nanobody and nucleic acid encoding sequence thereof, and uses of the same |
| US20240269276A1 (en) * | 2021-05-28 | 2024-08-15 | Harbour Biomed (Shanghai) Co., Ltd. | Specific binding protein targeting pd-l1 and cd73 |
| CN113045662B (zh) * | 2021-05-31 | 2021-08-13 | 西宝生物科技（上海）股份有限公司 | 一种特异性识别pd-l1的纳米抗体及其应用 |
| US20240327518A1 (en) * | 2021-08-06 | 2024-10-03 | Betta Pharmaceuticals Co., Ltd | Anti-pd-l1 nanobody and use thereof |
| KR20240045310A (ko) * | 2021-09-30 | 2024-04-05 | 베타 파머수티컬 컴퍼니 리미티드 | 이중특이성 항체 및 그 응용 |
| CN116410314A (zh) * | 2021-12-31 | 2023-07-11 | 博生吉医药科技(苏州)有限公司 | 一种新型pdl1单域抗体的开发 |
| CA3239434A1 (en) * | 2022-01-18 | 2023-07-27 | Fbd Biologics Limited | Cd47/pd-l1-targeting protein complex and methods of use thereof |
| IL321676A (en) * | 2022-12-29 | 2025-08-01 | Shanghai Henlius Biotech Inc | Anti-pdl1 antibodies and methods of use |
| EP4652201A1 (en) * | 2023-01-18 | 2025-11-26 | Elpiscience (Suzhou) Biopharma, Ltd. | Anti-pdl1 single domain antibody, fusion protein and use thereof |
| WO2025034806A1 (en) | 2023-08-08 | 2025-02-13 | Wisconsin Alumni Research Foundation | Single-domain antibodies and variants thereof against fibroblast activation protein |
| WO2025178959A1 (en) | 2024-02-20 | 2025-08-28 | University Of Georgia Research Foundation, Inc. | Single-domain antibodies and variants thereof against tab1 |
| US20260062453A1 (en) | 2024-07-30 | 2026-03-05 | Wisconsin Alumni Research Foundation | Degradation targeting agents and uses thereof |
| CN119119278B (zh) * | 2024-10-29 | 2025-03-21 | 海南大学 | 一种抗pd-l1蛋白的纳米抗体及其制备方法和应用 |
| CN119874915B (zh) * | 2025-01-23 | 2025-11-18 | 百吉生物医药(广州)股份有限公司 | 一种程序性死亡受体1的纳米抗体及其制备方法和应用 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2963712A1 (en) | 2014-10-21 | 2016-04-28 | Ablynx Nv | Treatment of il-6r related diseases |
| CN106243225B (zh) * | 2015-06-11 | 2021-01-19 | 智翔（上海）医药科技有限公司 | 新型抗-pd-l1抗体 |
| CN106397592A (zh) * | 2015-07-31 | 2017-02-15 | 苏州康宁杰瑞生物科技有限公司 | 针对程序性死亡配体(pd-l1)的单域抗体及其衍生蛋白 |
| CR20180279A (es) | 2015-11-18 | 2018-08-24 | Merck Sharp & Dohme | Enlazadores de ctla4 |
| AU2016360987A1 (en) | 2015-11-27 | 2018-06-07 | Ablynx Nv | Polypeptides inhibiting CD40L |
| CN106939047B (zh) | 2016-01-04 | 2021-08-31 | 江苏怀瑜药业有限公司 | 一种pd-l1抗体及其制备方法 |
| MX2018008308A (es) * | 2016-01-11 | 2019-05-15 | Inhibrx Inc | Proteinas de fusion de union a 41bb multivalentes y multiespecificas. |
| CN107216389B (zh) * | 2016-03-18 | 2022-03-29 | 和迈生物科技有限公司 | 抗pd-l1纳米抗体及其编码序列和用途 |
| PL3455257T3 (pl) * | 2016-05-09 | 2022-01-17 | Igm Biosciences Inc. | Przeciwciała anty-pd-l1 |
-
2018
- 2018-11-13 WO PCT/CN2018/115213 patent/WO2019096121A1/en not_active Ceased
- 2018-11-13 CA CA3081375A patent/CA3081375A1/en active Pending
- 2018-11-13 SG SG11202004144VA patent/SG11202004144VA/en unknown
- 2018-11-13 KR KR1020207016959A patent/KR102810657B1/ko active Active
- 2018-11-13 JP JP2020526566A patent/JP7410024B2/ja active Active
- 2018-11-13 EP EP18877388.1A patent/EP3710480A4/en active Pending
- 2018-11-13 CN CN201880074389.0A patent/CN111433224B/zh active Active
- 2018-11-13 US US16/764,411 patent/US11673954B2/en active Active
- 2018-11-13 AU AU2018366650A patent/AU2018366650B2/en active Active
- 2018-11-16 TW TW107140889A patent/TW201923083A/zh unknown
-
2020
- 2020-05-04 IL IL274438A patent/IL274438A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021503455A5 (enExample) | ||
| CN111454357B (zh) | 一种含有抗体的肿瘤治疗剂的开发和应用 | |
| US10913796B2 (en) | Antibodies targeting Fc receptor-like 5 and methods of use | |
| Revets et al. | Nanobodies as novel agents for cancer therapy | |
| JP2019533719A5 (enExample) | ||
| JP7649744B2 (ja) | Ｂｔｎ３ａ結合タンパク質及びその使用 | |
| JPWO2019129221A5 (enExample) | ||
| JP2013515508A5 (enExample) | ||
| JP2012525829A5 (enExample) | ||
| JP2018522888A5 (enExample) | ||
| JP2018093875A5 (enExample) | ||
| JP2013545738A5 (enExample) | ||
| JP2021508707A5 (enExample) | ||
| HRP20241013T1 (hr) | Protutijela za kelatirane radionuklide | |
| CA3196809A1 (en) | Combination treatment | |
| US20240117035A1 (en) | Cldn18.2/cd3 bispecific antibodies for the therapy of cldn18.2-expressing solid tumors | |
| JPWO2020114480A5 (enExample) | ||
| CN114667296B (zh) | 一种双特异性抗体及其用途 | |
| JP2020515277A5 (enExample) | ||
| JP2024001073A5 (enExample) | ||
| WO2022171100A1 (zh) | Gpc3人源化抗体及其应用 | |
| WO2022002033A1 (zh) | 具有H2L2与HCAb结构的结合蛋白 | |
| JPWO2019137541A5 (enExample) | ||
| JPWO2019201959A5 (enExample) | ||
| CA3235697A1 (en) | Anti-mesothelin nanobodies and use thereof |